Restoration of health through innovation



Parasitic diseases are global and world-wide travel and global warming have made geographic boundaries porous








We are Kainomyx 

We are committed to aiding the eradication of malaria worldwide. Our innovative approach is multifaceted – small molecule therapeutics is being partnered with the development of simple inexpensive diagnostic tools and other approaches to reduce and eventually eliminate the rate of transmission of malaria. Our platform will be effective for treatment of other parasitic diseases as well. Our approach is to target the force-producing cytoskeletal systems of the parasites, essential for parasite function.

Parasite division, morphogenesis, and host invasion are force-dependent processes

Cytoskeletal filament tracks propelled by force-producing molecular motors attached to a surface

“Watching the filaments move around like glowing worms reminded me that the motion inherent in life, so mysterious to the Greeks and early-twentieth-century researchers alike, was now without doubt explained by the amazing motions of mere molecules.”

“We have come a long way – from the vital forces of the ancients to the molecules of molecular biologists and biophysicists. If we are seeking the ‘life force,’ the force that animates life, then our search has been successful. This animating force is the random force of atoms, the jittering afterglow of the creation of the universe. The molecular machines, which take this undirected force and give it direction, embody the tight embrace of chance and necessity and are themselves the product of this embrace. Sculpted by evolution, the molecular machines of our bodies tame the molecular storm and turn it into the dance of life.”

Peter M. Hoffman, Life’s Ratchet, How Molecular Machines Extract Order from Chaos, published by Basic Books, a member of the Perseus Books Group, 2012.



April 15, 2020 – Three members have been added to the Board of Directors of Kainomyx.  William J. Rutter, PhD, co-Founder of the early biotech company Chiron and multiple additional companies, is Chairman of the Board of Kainomyx.  Rutter is Founder, Chairman and CEO of Synergenics, LLC, which controls a consortium of companies with different but complementary approaches to diagnosis, prevention and treatment on a worldwide basis.  He joins James Spudich, PhD, CEO of Kainomyx and co-founder of Cytokinetics and MyoKardia.  Dirk Thye, MD, serial entrepreneur who has led multiple small and medium sized companies in successful product development, and currently Executive Chairman at Geom Therapeutics, is an independent third member of the Board.  The fourth Board member is Amit L. Mehta, PhD, a Life Science Research Foundation Fellow at Bell Labs and Stanford University in his early career, became an Associate Partner at McKinsey and Company, followed by Managing Director positions at Morgan Stanley and Goldman Sachs, and is currently Managing Director at J.P. Morgan.